NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH. | June 9, 2021
June 10, 2021.
Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has completed a successful and fully subscribed unit offering bringing the company
SEK 50 million and that Biosergen’s share will be listed on Nasdaq First North Growth Market in
Stockholm on
June 24, 2021. The proceeds from the offering allow Biosergen to launch clinical trials of its antifungal drug candidate BSG005 with the ambition of filing for market approval in
the United States and
Europe by the end of 2025.
Biosergen develops BSG005, an antifungal drug candidate which has demonstrated a wide spectrum of antimycotic effects in several preclinical experimental models. To date, fungal infections cause more than 1.5 million deaths annually around the world, derived from systemic infections occurring in both natural environments and in hospitals. By addressing the sizeable need for new and effective antifungals, Biosergen is targeting a market with
Stockholm, June 10, 2021 - Nasdaq (Nasdaq: NDAQ) announces that trading in
Sivers Semiconductors AB's shares (short name SIVE) commence today on the
Nasdaq Stockholm Main Market. The company belongs to
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT IN WHOLE OR IN PART TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN ELICERA THERAPEUTICS AB. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.
Gothenburg, Sweden, June 10, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that it has received approval for admission to trading its share on the Nasdaq First North Growth Market. The first day for trading is Friday, June 11, 2021. &nb
STOCKHOLM, SWEDEN - June 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has completed a successful and fully subscribed unit offering